DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
Advances in the Development of Non-steroidal Mineralocorticoid-receptor Antagonists
The mineralocorticoid receptor (MR) belongs to the nuclear receptor superfamily
and regulates body fluid and electrolyte balance. In the last years, much effort
has been put into the development of non-steroidal MR antagonists that overcome
the side effects of the marketed steroid drugs, and can be used for the treatment
of hypertension and heart failure, among others. Initially, MR was identified in
epithelial cells, however it also plays important roles in non-epithelial tissues.
In this sense, it is of interest to discover ligands that might induce different MR
conformational changes, leading to specific coregulator interactions, which could
confer tissue-specific effects. Different series of non-steroidal ligands with diverse
central scaffolds has been described, which shows antihypertensive and cardiorenal
protective effects. This review covers a description of different non-steroidal MR
antagonist families, with special focus on compounds under clinical development.
The analysis of the three-dimensional (3D) structures of non-steroidal MR antagonists
in complex with the MR ligand-binding domain (LBD), recently reported,
highlights the interactions crucial for binding. The structure-activity relationships
of known ligands, together with the insights provided by the 3D structures of ligand
- LBD MR complexes, could help in the development of non-steroidal MR antagonists
with improved properties., This publication is based upon work from the EU COST Action ADMIRE
BM1301 in Aldosterone and Mineralocorticoid Receptor (MR) Physiology and
Pathophysiology (www.admirecosteu.com). Also supported by grants from
Ministerio de Economia y Competitividad (MINECO, Spain; grant SAF2015-66275-
C2-2-R and BFU2016-78374-R), CUNY (CCRG-1532), and the Hostos Office of
Academic Affairs, US National Institute of Health (NIGMS) SC2GM111231